Compare Moderna, Inc. (MRNA) vs Nano Dimension Ltd - ADR (NNDM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Nano Dimension Ltd - ADR — how do they compare? Moderna, Inc. trades at $225 (market cap $78.65B), while Nano Dimension Ltd - ADR trades at $1.55 (market cap $328.52M). The key difference: Moderna, Inc. is far larger — about 239.4× Nano Dimension Ltd - ADR's market cap, and Moderna, Inc. is trading nearer its 52-week high, Nano Dimension Ltd - ADR nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Moderna, Inc. for 59 Days and Nano Dimension Ltd - ADR for 43 Days on average.
| MRNA | NNDM | |
|---|---|---|
Market Cap | $78.65B | $328.52M |
Volume | 37,373,437 | 1,160,945 |
Sector | Health | Technology |
52-Week High | $203.46 | $2.14 |
52-Week Low | $22.36 | $1.21 |
Typical Hold Time | 59 Days | 43 Days |
Enterprise Value | $74.80B | -$76.33M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $197.00, up 0.26% on the day, with technical indicators showing a bullish trend and strong momentum. The stock has rallied over 500% in 2026, driven by positive clinical updates for its cancer vaccine pipeline and inclusion in the Nasdaq-100 index effective October 9, 2026. However, fundamentals remain challenging with revenue declining from $18.9B in 2022 to $1.9B in 2025 and negative net income margins exceeding 140%.
While technical momentum and pipeline optimism support near-term upside, valuation appears stretched with P/S of 35.08 and negative profitability metrics. Key risks include execution on non-COVID products, competitive pressure, and sustainability of recent gains. Analyst consensus is cautious with only 28% buy ratings and $115.70 price target suggesting significant downside from current levels.
Nano Dimension (NNDM) trades at $1.56, up 0.65% with a bearish technical signal. The company shows revenue growth from $102M in 2025 to $121M in 2026 but remains unprofitable with a -135% net margin. Recent strategic actions include cost-cutting initiatives and board changes, with cash reserves of $758M providing operational runway despite negative cash flows.
The outlook remains challenging with persistent losses and negative cash flow, though valuation ratios appear attractive with P/S of 2.73 and P/B of 0.68. Key risks include execution of turnaround strategy and competitive pressures in the industrial 3D printing sector. Analyst sentiment is cautious given the company's ongoing restructuring efforts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Nano Dimension Ltd - ADR
Nano Dimension Ltd is engaged in research and development of a three-dimensional printer that prints electronic circuit boards, also known as printed circuit boards, and ink materials and products based on nanotechnology. Its products consist of two main product lines - Dragonfly 2020 3D printer and proprietary ink products. The company's Dragonfly 2020 3D printer currently in development uses proprietary ink and integrated software to quickly create fully functioning PCB prototypes. Geographically, it generates maximum revenue from the USA followed by the Asia Pacific and Europe and Israel. It serves the Commercial, Research and Printing services industries.
Read more on NNDM →
